Outcome of the Board Meeting - Financial Results, Re-Appointment of Internal Auditor and Cost Auditor, Reconstitute of Risk Management Committee
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Drugs Ltd reported strong audited results for FY26. Consolidated revenue from operations grew to ₹2,38,703 lakhs (approximately ₹2,387 crore), up from ₹1,43,384 lakhs in FY25, representing revenue growth of about 66.5%. Profit after tax on consolidated basis surged to ₹21,090 lakhs compared to ₹4,055 lakhs in the previous year — a growth of over 420%. The company declared an un-modified audit opinion for both standalone and consolidated financial statements. Additionally, the board re-appointed M/s GMVP & Associates LLP as Cost Auditor for FY27 and M/s Raman S. Shah & Co. as Internal Auditor for 3 years. The Risk Management Committee was reconstituted with inclusion of Narendra J. Salvi as a member. Company operates only in the pharmaceuticals segment and has 3 subsidiaries with 2 step-down subsidiaries.
The company delivered exceptional financial performance with consolidated PAT growing over 5x year-on-year, indicating strong operational momentum and likely margin improvement. Clean audit opinion with no modifications supports financial reliability. Shareholders can view this positively given the substantial profit growth.